Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

3,454 questions · 3,562 findings · 816 reviews · Headline outcomes only

No studies found 538 · 15.1%GRADE not reported 239 · 6.7%Very low 933 · 26.2%Low 1,041 · 29.2%Moderate 612 · 17.2%High 199 · 5.6%

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) vs ANY DOSE ‐ short term

Leaving the study early: any reason ‐ when compared with high dose ( greater than or equal to 10 mg) · patients with schizophrenia

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) showed no clear difference in leaving the study early: Any reasons ‐ When compared with high dose… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

1000 mg/day omega‐3 fatty acid from flaxseed oil supplement vs placebo

Ulcer healing · people with diabetes and foot ulcers

It is very uncertain whether 1000 mg/day omega‐3 fatty acid from flaxseed oil supplement changes ulcer healing (absolute change in individual parameters of ulcer… compared with placebo (very low certainty).

4 findings from 1 review
Show 1 more finding

STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) vs ANY DOSE ‐ short term

Adverse effects: 5a. Movement disorders ‐ specific symptoms ‐ EPS: unspecified ‐ versus high dose ( greater than or equal to 10 mg) · patients with schizophrenia

STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) probably leads to lower adverse effects: EPS: unspecified ‐ Versus high dose (greater than… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

Topical imiquimod 5% (3 times/week) + meglumine antimoniate (IVMA) (20 mg/kg/d for 20 days) vs placebo + IVMA

Complete cure, at least 3 months after the end of treatment · People with American cutaneous leishmaniasis

Topical imiquimod 5% (3 times/week) + meglumine antimoniate (IVMA)… showed no clear difference in complete cure, at least 3 months after the end of treatment compared with placebo + IVMA (moderate certainty).

1 finding from 1 review

Pentoxifylline (oral 400 mg thrice daily) plus meglumine antimoniate (IMMA) (20 mg/ kg /day for 20 days) vs IMMA plus placebo

Complete cure, at least 3 months after the end of treatment · People with American cutaneous leishmaniasis

Pentoxifylline (oral 400 mg thrice daily) plus meglumine antimoniate… showed no clear difference in complete cure, at least 3 months after the end of treatment compared with IMMA plus placebo (moderate certainty).

1 finding from 1 review

Inositol supplementation IV initially followed by enteral administration (repeat doses of 80 mg/kg/day) in preterm infants born at less than 30 weeks' PMA vs placebo

Severe (grade 3 or greater) intraventricular hemorrhage (IVH) on cranial ultrasound ‐ not reported · preterm infants with or at risk of respiratory distress syndrome

Inositol supplementation IV initially followed by enteral… showed no clear difference in severe IVH (grade 3 or 4) compared with placebo (moderate certainty).

1 finding from 1 review

Inositol supplementation IV initially followed by enteral administration (repeat doses of 80 mg/kg/day) in preterm infants born at less than 30 weeks' PMA vs placebo

Any late‐onset sepsis ‐ all infants · preterm infants with or at risk of respiratory distress syndrome

Inositol supplementation IV initially followed by enteral… showed no clear difference in late‐onset sepsis (> 72 hours of age) compared with placebo (high certainty).

1 finding from 1 review

Inositol supplementation IV initially followed by enteral administration (repeat doses of 80 mg/kg/day) in preterm infants born at less than 30 weeks' PMA vs placebo

Necrotizing enterocolitis (suspected or proven) · preterm infants with or at risk of respiratory distress syndrome

Inositol supplementation IV initially followed by enteral… showed no clear difference in suspected or proven NEC compared with placebo (high certainty).

1 finding from 1 review